This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
by Ahan Chakraborty
NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
by Zacks Equity Research
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
UTHRNegative Net Change AMRNNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
by Kanishka Das
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TGTXPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechs
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
by Zacks Equity Research
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
NVSNegative Net Change BAYRYPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
by Ekta Bagri
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
LQDAPositive Net Change JNJNegative Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
by Kanishka Das
ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.
ATAIPositive Net Change CMPSNegative Net Change GHRSNegative Net Change
biotechs
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
by Kanishka Das
ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.
ATAIPositive Net Change CMPSNegative Net Change GHRSNegative Net Change
biotechs
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
by Ahan Chakraborty
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
TNGXNegative Net Change RVMDPositive Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
by Kanishka Das
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
ATAIPositive Net Change CMPSNegative Net Change GHRSNegative Net Change
biotechs
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
by Ahan Chakraborty
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGXNegative Net Change RVMDPositive Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals